SCHEMBL18006252

SCHEMBL18006252

Cc1ccccc1OCc1cccc(-c2nn[nH]c2C#N)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 3/20 0.39
SGMS2 Q8NHU3 2/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR6 P50406 2/20 0.38
SLC22A12 Q96S37 1/20 0.37
FFAR1 O14842 2/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
NPC1 O15118 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26070864 0.89 MRGPRX4 (0.44) MRGPRX4LMNAHPGDKMT2AHTR6
SCHEMBL18006250 0.89 MRGPRX4 (0.44) MRGPRX4LMNAMAPTL3MBTL1NPC1
SCHEMBL18004692 0.86 SMN1; SMN2 (0.44) MRGPRX4LMNAHPGDKMT2AMAPT
SCHEMBL18006258 0.86 MRGPRX4 (0.44) MRGPRX4LMNAHPGDMAPTMAPK1
SCHEMBL18006267 0.86 HTR1A (0.43) MRGPRX4SGMS2KMT2AHTR6NISCH
SCHEMBL18006265 0.85 MRGPRX4 (0.46) MRGPRX4LMNAHPGDKMT2AMAPT
SCHEMBL18004712 0.84 CYP11B1 (0.38) MRGPRX4HTR6FFAR1
SCHEMBL18006303 0.84 MRGPRX4 (0.37) MRGPRX4KMT2AMAPTSMN1; SMN2
SCHEMBL18006263 0.84 FFAR1 (0.41) MRGPRX4FFAR1MAPTL3MBTL1RXRA
SCHEMBL18004688 0.84 MRGPRX4 (0.47) MRGPRX4SGMS2FFAR1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 MRGPRX4 4062/4885SGMS2 991/4885LMNA 4192/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 MRGPRX4 4062/4885SGMS2 991/4885LMNA 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.